Patents Assigned to Coley Pharmacuetical Group, Inc.
-
Publication number: 20040167089Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: ApplicationFiled: January 30, 2004Publication date: August 26, 2004Applicants: The University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040162262Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: August 19, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The U.S.A., as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040162258Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: January 30, 2004Publication date: August 19, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040152656Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: August 5, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20040142469Abstract: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides that do not contain unmethylated CpG sequences (i.e. methylated CpG sequences or no CpG sequence) to outcompete unmethylated CpG nucleic acids for binding. Further disclosed are methylated CpG containing dinucleotides for use antisense therapies or as in vivo hybridization probes, and immunoinhibitory oligonucleotides for use as antiviral therapeutics.Type: ApplicationFiled: February 26, 2004Publication date: July 22, 2004Applicants: University of Iowa Research Foundation, Coley Pharmacuetical Group, Inc., The USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg